DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 59 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $3,596,000 | -71.2% | 368,042 | 0.0% | 0.00% | -66.7% |
| Q3 2021 | $12,506,000 | -9.6% | 368,042 | -2.6% | 0.00% | 0.0% |
| Q2 2021 | $13,834,000 | -5.0% | 377,879 | +16.3% | 0.00% | 0.0% |
| Q1 2021 | $14,567,000 | -41.2% | 324,868 | -25.1% | 0.00% | -50.0% |
| Q4 2020 | $24,762,000 | +8.5% | 433,882 | -2.5% | 0.01% | 0.0% |
| Q3 2020 | $22,821,000 | -1.5% | 444,860 | +14.6% | 0.01% | -14.3% |
| Q2 2020 | $23,176,000 | +213.9% | 388,079 | +116.4% | 0.01% | +133.3% |
| Q1 2020 | $7,384,000 | +5.9% | 179,355 | -46.0% | 0.00% | 0.0% |
| Q4 2018 | $6,974,000 | -64.0% | 332,261 | -33.5% | 0.00% | -50.0% |
| Q3 2018 | $19,360,000 | -1.6% | 500,000 | 0.0% | 0.01% | -14.3% |
| Q2 2018 | $19,675,000 | +1209.0% | 500,000 | +566.7% | 0.01% | +600.0% |
| Q1 2018 | $1,503,000 | -11.6% | 75,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $1,700,000 | +19.4% | 75,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,424,000 | – | 75,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
| SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
| PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
| Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
| EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
| Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
| VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |